When it comes to determining acceptable radiation dose, a distinction needs to be made between small-, medium-, and large-field cone-beam CT (CBCT) scanners and protocols, according to a new study in ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with ...
- Zilebesiran Met Primary Endpoint Demonstrating Greater than 15 mmHg Reduction of Systolic Blood Pressure at Three Months of Treatment Compared to Placebo at Two Highest Single Doses Evaluated - - ...
(RTTNews) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Thursday positive topline results from the KARDIA-1 Phase 2 study of zilebesiran. zilebesiran is an investigational ...
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to receive a single ...
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...
Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and ...
The dose escalation of biologic therapy was effective in achieving remission in up to approximately half of patients with inflammatory bowel disease (IBD), with a probability of sustaining the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback